Wilbanks Smith & Thomas Asset Management LLC Sells 1,965 Shares of Merck & Co., Inc. (NYSE:MRK)

Wilbanks Smith & Thomas Asset Management LLC lowered its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 4.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 44,090 shares of the company’s stock after selling 1,965 shares during the period. Wilbanks Smith & Thomas Asset Management LLC’s holdings in Merck & Co., Inc. were worth $3,379,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of MRK. Financial Avengers Inc. boosted its holdings in Merck & Co., Inc. by 115.8% in the 4th quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock valued at $25,000 after purchasing an additional 176 shares during the period. Moisand Fitzgerald Tamayo LLC boosted its holdings in Merck & Co., Inc. by 78.0% in the 4th quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock valued at $27,000 after purchasing an additional 156 shares during the period. Retirement Group LLC boosted its holdings in Merck & Co., Inc. by 116.4% in the 3rd quarter. Retirement Group LLC now owns 608 shares of the company’s stock valued at $30,000 after purchasing an additional 327 shares during the period. Bellwether Advisors LLC boosted its holdings in Merck & Co., Inc. by 460.0% in the 3rd quarter. Bellwether Advisors LLC now owns 420 shares of the company’s stock valued at $31,000 after purchasing an additional 345 shares during the period. Finally, Steward Financial Group LLC bought a new stake in Merck & Co., Inc. in the 4th quarter valued at about $40,000. 72.05% of the stock is owned by hedge funds and other institutional investors.

NYSE MRK traded up $0.11 on Friday, hitting $88.69. The company’s stock had a trading volume of 15,914,164 shares, compared to its average volume of 10,794,321. The company has a quick ratio of 1.02, a current ratio of 1.27 and a debt-to-equity ratio of 0.80. Merck & Co., Inc. has a 1-year low of $70.89 and a 1-year high of $91.40. The company’s 50-day moving average is $81.53 and its 200 day moving average is $80.10. The firm has a market cap of $224.19 billion, a PE ratio of 15.87, a PEG ratio of 1.19 and a beta of 0.45.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.83 by $0.31. Merck & Co., Inc. had a net margin of 26.02% and a return on equity of 47.24%. The firm had revenue of $15.90 billion during the quarter, compared to analysts’ expectations of $14.64 billion. During the same period in the prior year, the company posted $1.40 EPS. The company’s revenue was up 31.6% on a year-over-year basis. On average, equities analysts expect that Merck & Co., Inc. will post 7.27 EPS for the current year.

Several equities analysts have recently commented on MRK shares. Barclays boosted their target price on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research report on Tuesday, April 12th. SVB Leerink dropped their target price on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. Mizuho started coverage on shares of Merck & Co., Inc. in a research report on Friday, April 1st. They issued a “buy” rating and a $100.00 target price for the company. Morgan Stanley dropped their target price on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a research report on Friday, January 28th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Buy” and an average target price of $90.69.

Merck & Co., Inc. Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.